{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:31:32Z","timestamp":1761647492545,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015090","name":"Imam Abdulrahman Bin Faisal University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Taibah University Medical Sciences"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jtumed.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:33:56Z","timestamp":1589243636000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antimicrobial activity of cephalosporin\u2013beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-6002","authenticated-orcid":false,"given":"Amani M.","family":"Alnimr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha M.","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtumed.2020.04.004_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02671-16","article-title":"Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria","volume":"61","author":"Thaden","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jtumed.2020.04.004_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/0256-4947.67073","article-title":"Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia","volume":"30","author":"Al Johani","year":"2010","journal-title":"Ann Saudi Med"},{"issue":"3","key":"10.1016\/j.jtumed.2020.04.004_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.jtumed.2020.04.004_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A\u00a0review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.jtumed.2020.04.004_bib5","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","article-title":"Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa","volume":"43","author":"Bonomo","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtumed.2020.04.004_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.07.022","article-title":"Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains","volume":"44","author":"Tsai","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jtumed.2020.04.004_bib7","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards."},{"key":"10.1016\/j.jtumed.2020.04.004_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob Resist Infect Contr"},{"issue":"30","key":"10.1016\/j.jtumed.2020.04.004_bib9","first-page":"5528","article-title":"Antimicrobial resistance pattern and prevalence of metallo-\u03b2-lactamases in Pseudomonas aeruginosa from Saudi Arabia","volume":"5","author":"Alagamy","year":"2011","journal-title":"Afr J Microbiol Res"},{"issue":"1","key":"10.1016\/j.jtumed.2020.04.004_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5144\/0256-4947.2016.23","article-title":"Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah","volume":"36","author":"Khan","year":"2016","journal-title":"Ann Saudi Med"},{"issue":"7","key":"10.1016\/j.jtumed.2020.04.004_bib11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/jac\/dks091","article-title":"Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia","volume":"67","author":"Memish","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jtumed.2020.04.004_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.jtumed.2020.04.004_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jtumed.2020.04.004_bib14","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/jac\/dkx181","article-title":"Sparing carbapenem usage","volume":"72","author":"Wilson","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jtumed.2020.04.004_bib15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jtumed.2020.04.004_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.jtumed.2020.04.004_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Contr"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000135","article-title":"Communicating trends in resistance using a drug resistance index","volume":"1","author":"Laxminarayan","year":"2011","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jtumed.2020.04.004_bib19","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3201\/eid2510.181699","article-title":"Risk factors for carbapenem-resistant Pseudomonas aeruginosa, Zhejiang Province, China","volume":"25","author":"Hu","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193431","article-title":"Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections","volume":"13","author":"Palavutitotai","year":"2018","journal-title":"PloS One"},{"issue":"Suppl 1","key":"10.1016\/j.jtumed.2020.04.004_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7883\/yoken.67.118","article-title":"Appropriate sampling sites for the surveillance of multidrug-resistant Pseudomonas aeruginosa colonization","volume":"67","author":"Araoka","year":"2014","journal-title":"Jpn J Infect Dis"},{"issue":"1","key":"10.1016\/j.jtumed.2020.04.004_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13054-019-2371-3","article-title":"Multidrug resistant gram-negative bacteria in community-acquired pneumonia","volume":"23","author":"Cilloniz","year":"2019","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jtumed.2020.04.004_bib24","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1128\/AAC.01947-13","article-title":"Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model","volume":"58","author":"Wiskirchen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtumed.2020.04.004_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.jtumed.2020.04.004_bib26","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation beta-Lactam\/beta-Lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtumed.2020.04.004_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jgar.2019.01.032","article-title":"Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis","volume":"18","author":"Acar","year":"2019","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"12","key":"10.1016\/j.jtumed.2020.04.004_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtumed.2020.04.004_bib30","first-page":"1","article-title":"Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary","author":"O'Neall","year":"2020","journal-title":"Acta Microbiol Immunol Hung"},{"key":"10.1016\/j.jtumed.2020.04.004_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/IDR.S243301","article-title":"First study of antimicrobial activity of ceftazidime-avibactam and ceftolozane-tazobactam against Pseudomonas aeruginosa isolated from patients with urinary tract infection in Tehran, Iran","volume":"13","author":"Rahimzadeh","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jtumed.2020.04.004_bib32","doi-asserted-by":"crossref","first-page":"4379686","DOI":"10.1155\/2016\/4379686","article-title":"Diversity of molecular mechanisms conferring carbapenem resistance to Pseudomonas aeruginosa isolates from Saudi Arabia","volume":"2016","author":"Al-Agamy","year":"2016","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"6","key":"10.1016\/j.jtumed.2020.04.004_bib33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1099\/jmm.0.000730","article-title":"Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region","volume":"67","author":"Zowawi","year":"2018","journal-title":"J\u00a0Med Microbiol"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.00834-09","article-title":"Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains","volume":"54","author":"Juan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_3","key":"10.1016\/j.jtumed.2020.04.004_bib35","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jtumed.2020.04.004_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki280","article-title":"Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-{beta}-lactamase gene from Saudi Arabia","volume":"56","author":"Guerin","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/CMR.18.2.306-325.2005","article-title":"Metallo-beta-lactamases: the quiet before the storm?","volume":"18","author":"Walsh","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.jtumed.2020.04.004_bib38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jtumed.2020.04.004_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtumed.2020.04.004_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jtumed.2020.04.004_bib41","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ccr3.1612","article-title":"Failure of ceftolozane-tazobactam salvage therapy in complicated pneumonia with lung abscess","volume":"6","author":"Lewis","year":"2018","journal-title":"Clin Case Rep"},{"issue":"2","key":"10.1016\/j.jtumed.2020.04.004_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001315","article-title":"Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index","volume":"4","author":"Klein","year":"2019","journal-title":"BMJ Glob Health"}],"container-title":["Journal of Taibah University Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361220300640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361220300640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:27:27Z","timestamp":1761647247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1658361220300640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1658361220300640"],"URL":"https:\/\/doi.org\/10.1016\/j.jtumed.2020.04.004","relation":{},"ISSN":["1658-3612"],"issn-type":[{"type":"print","value":"1658-3612"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of cephalosporin\u2013beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains","name":"articletitle","label":"Article Title"},{"value":"Journal of Taibah University Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtumed.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Production and hosting by Elsevier Ltd on behalf of Taibah University.","name":"copyright","label":"Copyright"}]}}